Research Analysts’ Recent Ratings Changes for Amgen (AMGN)

Several brokerages have updated their recommendations and price targets on shares of Amgen (NASDAQ: AMGN) in the last few weeks:

• 4/13/2026 – Amgen had its price target raised by UBS Group AG from $390.00 to $400.00. They now have a “buy” rating on the stock.
• 4/11/2026 – Amgen was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/10/2026 – Amgen had its price target raised by Morgan Stanley from $309.00 to $326.00. They now have an “equal weight” rating on the stock.
• 4/9/2026 – Amgen had its price target raised by Guggenheim from $347.00 to $351.00. They now have a “neutral” rating on the stock.
• 4/8/2026 – Amgen had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $350.00 price target on the stock.
• 4/7/2026 – Amgen had its price target raised by Royal Bank Of Canada from $360.00 to $370.00. They now have an “outperform” rating on the stock.
• 3/19/2026 – Amgen had its price target raised by Wells Fargo & Company from $375.00 to $390.00. They now have an “equal weight” rating on the stock.
• 3/10/2026 – Amgen is now covered by Jefferies Financial Group Inc.. They set a “hold” rating and a $350.00 price target on the stock.
• 3/5/2026 – Amgen had its “market perform” rating reaffirmed by Leerink Partners. They now have a $355.00 price target on the stock.
• 2/21/2026 – Amgen was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/20/2026 – Amgen is now covered by Barclays PLC. They set an “equal weight” rating and a $350.00 price target on the stock.
• 2/19/2026 – Amgen was given a new $185.00 price target by Barclays PLC. They now have an “equal weight” rating on the stock.
• 2/19/2026 – Amgen had its price target raised by Wells Fargo & Company from $325.00 to $375.00. They now have an “equal weight” rating on the stock.
• 2/19/2026 – Amgen was upgraded by Barclays PLC to “hold”.
• 2/18/2026 – Amgen had its price target raised by Piper Sandler from $381.00 to $432.00. They now have an “overweight” rating on the stock.
• 2/18/2026 – Amgen had its price target raised by Rothschild & Co Redburn from $180.00 to $200.00. They now have a “sell” rating on the stock.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.